Trial Outcomes in Kidney Disease : Nephmadness 2018

The "3 Ds" of death, dialysis, and doubling of creatinine has been the major outcome assessed in nephrology studies for years. More recently, there has been an increased interest in using other surrogate markers such as 40% reduction in eGFR and proteinuria in nephrology studies. This region explores the use of these surrogate markers as trial endpoints as well as analyzes the use of patient-reported outcomes in clinical trials.

Check out the full NephMadness Trial Outcomes Region here

Target Audience

  • Physicians 

Learning Objectives

After participation in this activity, learners will be able to:

  • Recognize traditional hard outcomes of nephrology trials and compare them to newer outcomes being used in shorter trials
METHOD OF PARTICIPATION:
    • Read the educational summary for the Trial Outcomes Region here
    • Make sure you completed a bracket with your predictions of what concepts are the most important or most impactful here
    • Participate in social media (Twitter, Instagram, Facebook, blogs) discussions about these concepts, sharing your opinions of what is the most important or impactful to you in nephrology.  
    • Login or create an account to this site and complete the evaluations and download certificate.
    Course summary
    Available credit: 
    • 1.00 AMA PRA Category 1 Credit™
    Course opens: 
    03/15/2018
    Course expires: 
    06/15/2018
    Cost:
    $0.00
    Parent activity set: 
    Rating: 
    0

    Perry Wilson, MD, MSCE
    Assistant Professor of Medicine 
    Yale School of Medicine 
    New Have, CT  
    Disclosure: Has no financial relationships with commercial interest(s).

    Planning Committee Disclosures

    Anna Burgner, MD, MEHP
    Assistant Professor 
    Vanderbilt Medical Center
    Nashville, TN 
    Disclosure: Primary Investigator: Bayer (Diabetic Nephropathy); inRegen (Diabetic Nephropath); AstraZeneca (CKD); Fibrogen (Anemia)

    Jamie P. Dwyer, MD
    Professor of Medicine
    Vanderbilt University Medical Center
    Nashville, TN
    Disclosure: Research Funding: AstraZeneca (CKD); Sanofi (CKD); TIMI Group (CKD). 

    Danielle Nathan, MA
    Professional Education Director
    National Kidney Foundation
    New York, NY
    Disclosure: Has no financial relationships with commercial interest(s).

    Kathryn Troy, MPH
    Professional Education Coordinator
    National Kidney Foundation
    New York, NY
    Disclosure: Has no financial relationships with commercial interest(s).

    DECLARATION OF DISCLOSURE:

    It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity.  

    If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest Policy.

    UNLABELED/INVESTIGATIONAL USE:

    During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

    The National Kidney Foundation is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.


     

    Physician

    The National Kidney Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Available Credit

    • 1.00 AMA PRA Category 1 Credit™

    Accreditation Period

    Course opens: 
    03/15/2018
    Course expires: 
    06/15/2018

    Price

    Cost:
    $0.00
    Please login or register for a PERC account to take this course.
    DISCLAIMER:

    The faculty and National Kidney Foundation (NKF) do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

    Information contained in this NKF educational resource is based upon current data available at the time of publication. Information is intended to help clinicians become aware of new scientific findings and developments.  This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management.

    Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.